San Diego, CA, United States of America

Michael Brennan Wallace

This inventor holds 94 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 24 EPO patents, primarily in Histone Demethylase Inhibitors (CPC class C07D401-12). Top assignees: Celgene Quanticel Research, Inc., Takeda Pharmaceutical Company Limited, Agouron Pharmaceuticals, Inc.. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Brennan Wallace. Retrieved from https://idiyas.com/inventor/michael-brennan-wallace

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 94 

% Patents Active = 73.4

 

 

Average Co-Inventor Count = 4.1

ph-index = 13

Forward Citations = 965(Granted Patents)

Forward Citations (Not Self Cited) = 855(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Location History:

  • San Siego, CA (US) (2018)
  • San Diego, CA (US) (2002 - 2024)

Company Filing History:


Years Active: 2002-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Histone Demethylase
Inhibitors
Therapeutic Compounds
Epigenetics
Cancer Treatment
Drug Discovery
Biochemical Pathways
Gene Regulation
Pharmacology
Molecular Biology
Enzyme Inhibition
Chemical Biology
94 patents (USPTO):Explore Patents

Title: Michael Brennan Wallace: A Visionary Inventor Shaping the Future

Introduction:

Michael Brennan Wallace, a pioneering inventor based in San Diego, CA, is known for his relentless pursuit of innovation and commitment to pushing the boundaries of what is possible in the world of inventions. With a remarkable 93 patents to his name, Wallace continues to inspire the next generation of inventors to think boldly and create solutions that shape the future.

Latest Patents:

Wallace's latest patents showcase his expertise in developing groundbreaking therapeutic compounds and histone demethylase inhibitors. These inventions are aimed at addressing diseases mediated by aberrant cell signaling, such as inflammatory disorders, cancer, and neoplastic diseases. Particularly noteworthy is his work on compounds exhibiting selective inhibitory activity against CBP compared with BRD4, highlighting his deep understanding of epigenetic regulation.

Career Highlights:

Throughout his illustrious career, Wallace has made significant contributions to the field of biopharmaceuticals. He has garnered experience working at prestigious companies such as Celgene Quanticel Research, Inc., and Takeda Pharmaceutical Company Limited. His innovative spirit and dedication to advancing medical research have led to the development of novel treatments for a variety of complex diseases.

Collaborations:

Wallace has collaborated with esteemed professionals in the industry, including Jeffrey Alan Stafford and James Marvin Veal. Together, they have pushed the boundaries of scientific discovery and paved the way for groundbreaking innovations in healthcare. Their collective expertise has resulted in transformative advancements that have the potential to revolutionize the field of oncology and beyond.

Conclusion:

In conclusion, Michael Brennan Wallace's contributions to the world of inventions are truly remarkable. His visionary approach to problem-solving and his unwavering dedication to making a positive impact on society set him apart as a true pioneer in his field. As Wallace's work continues to inspire and influence the next generation of inventors, the future of innovation looks brighter than ever before.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…